Organon & Co. Common Stock vs Packaging Corporation of America — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Packaging Corporation of America trades at $229.41 (market cap $20.64B). The key difference: Packaging Corporation of America is far larger — about 5.7× Organon & Co. Common Stock's market cap, and Packaging Corporation of America pays the higher dividend (2.59%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Packaging Corporation of America for 47 Days on average.
| OGN | PKG | |
|---|---|---|
Market Cap | $3.62B | $20.64B |
Volume | 2,892,999 | 529,375 |
Sector | Health | Consumer Cyclical |
52-Week High | $13.81 | $257.43 |
52-Week Low | $5.70 | $191.68 |
Typical Hold Time | 0 Days | 47 Days |
Enterprise Value | $11.04B | $24.45B |
Dividend Yield | 0.58% | 2.59% |
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Packaging Corporation of America (PKG) trades at $231.65, up 1.68% on the day, with a bearish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q1 and Q2 2026 but missing in Q4 2025, while revenue is projected to grow to $9.5B in 2026. Analyst consensus is a 'Hold' with a $272.43 price target, and the stock offers a $1.50 quarterly dividend. Recent news highlights institutional investments and upcoming Q3 earnings discussion.
PKG presents a cautious outlook with steady revenue growth offset by margin pressures, as net income is expected to decline to $692M in 2026. The primary opportunity lies in the consensus price target suggesting ~18% upside, but risks include rising costs, competitive pressures, and bearish technical trends. Investors should weigh the dividend yield against earnings volatility and valuation multiples above sector averages.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →Packaging Corporation of America is a leading producer of containerboard and corrugated packaging products in North America. The company also produces white papers, which include printing and writing papers. PKG operates as an integrated manufacturer, with a strong focus on high-quality and sustainable packaging solutions for e-commerce, food and beverage, and other industrial and consumer markets.
Read more on PKG →